Dupuytren Disease Market Share, Size, Trends, Industry Analysis Report, By Type (Diagnosis, Treatment); By Disease Type (Type I, Type II, Type III); By End-use (Hospitals, Clinics, Academic & Research Institute, Others); By Region, And Segment Forecasts, 2023 - 2032
- Published Date:Oct-2023
- Pages: 116
- Format: PDF
- Report ID: PM3797
- Base Year: 2022
- Historical Data: 2019-2021
Report Outlook
The global dupuytren disease market was valued at USD 4.08 billion in 2022 and is expected to grow at a CAGR of 5.1% during the forecast period.
Market is witnessing remarkable growth due to the rising prevalence of the disease. As per the recent study in the Journal of Hand Surgery has shown a significant increase in the diagnosed cases, representing a growing number of patients requiring treatment options. Consequently, pharmaceutical companies and medical device manufacturers are making higher investments in research and development to meet the demand for effective management approaches. Furthermore, as per the 2021 population survey in the U.S. revealed that around 7 percent of the population clinical symptoms, with over a third of this group facing the impact of the Dupuytren’s contractures on their daily functioning.
To Understand More About this Research: Request a Free Sample Report
In the healthcare industry, various stakeholders now have a unique chance to contribute towards improving treatment options and optimizing disease management, ultimately resulting in better patient outcomes worldwide. The market is experiencing a surge in collaborations and partnerships among key players, leading to a wider array of product offerings and innovative advancements. An illustrative example of this trend is seen in the acquisition of BioSpecific Technologies by the Endo International in October 2020, which holds the promise of expanding treatment options for Dupuytren's disease and improving production capabilities.
The market is expected to present promising opportunities due to the increasing focus on research and development and the emergence of new markets. With a significant lack of effective treatments for various medical conditions, coupled with advancements in healthcare technology, the market's prospects appear optimistic. Particularly noteworthy is the successful Phase 2a clinical trial conducted by 180 Therapeutics on anti-TNF therapy in Dupuytren's disease, which represents a major achievement. As a result, it opens avenues for further exploration and research on the therapy, ultimately aiming to address the unmet needs of patients and transform the treatment landscape.
For Specific Research Requirements, Request for a Customized Report
Industry Dynamics
Growth Drivers
Rising Prevalence of Research Activities
Market growth is driven by the rising prevalence of medical research and technological advancements. This expansion opens opportunities for stakeholders to address the changing requirements of patients and improve disease management results. In the field of hand surgery, the Journal of Hand Surgery highlights the importance of exploring alternative nonsurgical methods to treat Dupuytren's disorder. This emphasis fosters ongoing discussions among hand surgeons concerning innovative therapies and approaches. The review article delves into potential treatment options that seek to reduce the risks associated with invasive procedures and lower the chances of recurrence, ultimately benefiting patients and healthcare providers alike.
Report Segmentation
The market is primarily segmented based on disease type, type, end use, and region.
|
By Disease Type |
By Type |
By End Use |
By Region |
|
|
|
|
To Understand the Scope of this Report: Speak to Analyst
By Disease type analysis
Disease type II segment accounted for the largest share in 2022
Disease type II accounted for major global share. This form of the condition is characterized by the involvement of the palmar fascia and digital cords, leading to finger flexion deformities. Extensive research on the global prevalence of the disease confirms that type II accounts for a significant proportion of diagnosed cases, highlighting its higher prevalence and substantial impact on patients.
The prominence of type II Dupuytren's disease emphasizes the urgent requirement for effective treatment options and management approaches to tackle the complexities associated with finger deformities. Consequently, pharmaceutical companies and medical device manufacturers are dedicating greater attention to the development of innovative therapies and interventions that specifically target type II Dupuytren's disorder. This concerted effort aims to meet the increasing demands of the patient population and provide them with improved solutions to address the challenges posed by this form of the condition.
By Type analysis
Treatment segment expected to hold substantial market share in 2022
Treatment segment is projected to hold significant market share. This dominance can be attributed to the growing emphasis on developing effective treatment options aimed at managing the disease and enhancing the overall well-being of patients. Pharmaceutical companies and medical device manufacturers have been actively involved in extensive research and development endeavors, focusing on introducing innovative approaches to treatment.
Advancements in medical technology and surgical techniques have been instrumental in driving the market's growth by providing a diverse range of treatment options. This includes both non-invasive therapies and surgical procedures, granting healthcare professionals the flexibility to customize treatment strategies according to individual patient requirements. Furthermore, the increasing recognition of the importance of early diagnosis and intervention among both patients and healthcare providers has played a significant role in the treatment segment's domination. As the healthcare industry endeavors to meet patient demands, engages in continuous research and development, and promotes rising awareness, the market is expected to continue its upward trajectory.
By End-Use analysis
Hospitals segment expected to hold substantial market share in 2022
Hospitals segment is projected to hold significant market share. Hospitals are equipped with dedicated departments that focus on hand surgery and rehabilitation. Their advanced infrastructure, including operating rooms, enables them to perform intricate procedures. These centers are specifically dedicated to catering to patients suffering from this condition, offering centralized support and comprehensive care from the initial diagnosis through treatment and rehabilitation stages. As a result of these factors, the hospital segment continues to play a pivotal role in providing top-quality healthcare services for Dupuytren's disease patients.
Clinics segment is projected to witness the highest growth rate. This growth can be attributed to the appeal of clinics that provide specialized care for Dupuytren's disease, attracting patients who seek targeted management with reduced waiting times and flexible scheduling options. Clinics offer easy access to minimally invasive procedures, presenting less disruptive treatment choices and faster recovery for patients. Furthermore, the establishment of the specialized Dupuytren's disease clinics in the urban areas is catering to the comprehensive needs of patients, contributing to the segment's expansion. These clinics fulfill the rising demand for personalized care and specialized expertise in managing the condition, further driving the segment’s growth.
Regional Insights
Europe region dominated the global market in 2022
Europe dominated the global market. Europe's leadership in addressing these medical needs is solidified by the recent approval of the Xiapex by the Biovitrum AB (publ) top treat Dupuytren's contracture & Peyronie's disease. This approval demonstrates Europe's proactive approach to providing effective treatment options and highlights the region's prominence in the field of healthcare. As industry players collaborate and introduce groundbreaking therapies, Europe continues to be at the forefront of medical advancements, ultimately benefiting individuals affected by these conditions.
APAC is likely to emerge as fastest growing region. Region has witnessed significant advancements in medical technologies, with the introduction of collagenase injection therapy being a notable example. This innovative treatment offers patients a minimally invasive alternative to surgery and has gained popularity, particularly in countries like Japan and South Korea. These advancements in medical technology have contributed to the region's attractiveness as a rapidly growing market for Dupuytren's disease treatment options.
Key Market Players & Competitive Insights
The dupuytren disease market is fragmented and is anticipated to witness competition due to several players' presence. Major service providers in the market are constantly upgrading their technologies to stay ahead of the competition and to ensure efficiency, integrity, and safety. These players focus on partnership, product upgrades, and collaboration to gain a competitive edge over their peers and capture a significant market share.
Some of the major players operating in the global market include
- Actiza Pharmaceutical
- AstraZeneca
- Bayer
- Bristol-Meyers
- Endo International
- Fresenius Kabi
- GSK
- Hikma Pharmaceuticals
- LEO Pharma
- Nantong Jinghua Pharmaceutical
- Novartis
- Pfizer
- Spear Pharmaceuticals
Recent Developments
- In April 2023, Ventoux Biosciences is a company committed to revolutionizing the treatment of fibrotic diseases, including Dupuytren's disease. Their primary focus lies in providing transformative therapies that have the potential to significantly improve patients' lives. To achieve this goal, the company has initiated the pre-clinical evaluation of their early-stage pipeline, which includes promising candidates VEN-201 and VEN-202.
- In June 2023, Endo International has recently begun enrolling patients for the GRASP-DC (Generating Real-world Ambi-spective Data to Study Participant Treatment Outcomes for Dupuytren's Contracture) registry. This registry aims to include 1,000 patients diagnosed with Dupuytren's disease, providing valuable real-world data to study and analyze treatment outcomes for the condition.
Dupuytren Disease Market Report Scope
|
Report Attributes |
Details |
|
Market size value in 2023 |
USD 4.18 billion |
|
Revenue forecast in 2032 |
USD 6.52 billion |
|
CAGR |
5.1% from 2023 – 2032 |
|
Base year |
2022 |
|
Historical data |
2019 – 2021 |
|
Forecast period |
2023 – 2032 |
|
Quantitative units |
Revenue in USD billion and CAGR from 2023 to 2032 |
|
Segments covered |
By Disease Type, By Type, By End Use, By Region |
|
Regional scope |
North America, Europe, Asia Pacific, Latin America; Middle East & Africa |
|
Customization |
Report customization as per your requirements with respect to countries, region and segmentation. |
FAQ's
key companies in dupuytren disease market are Bayer, Novartis, Pfizer, Nantong Jinghua Pharmaceutical.
The global dupuytren disease market is expected to grow at a CAGR of 5.1% during the forecast period.
The dupuytren disease market report covering key segments are disease type, type, end use, and region.
key driving factors in industrial dupuytren disease market are Increasing aging population worldwide
The global Dupuytren disease market size is expected to reach USD 6.52 billion by 2032.
